Physician profile
Lori Siegel
NPI 1730144882
$1,504,279.12
in general payments reported to CMS, 2019-2025
28 companies · $241K in 2025
The $241K reported for 2025 was more than what 99% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $267K · 2020: $144K · 2021: $157K · 2022: $215K · 2023: $208K · 2024: $274K · 2025: $241K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $527K · Travel and Lodging: $91K · Consulting Fee: $80K · Food and Beverage: $23K · Education: $313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $526,681.50 |
| Travel and Lodging | $91,474.58 |
| Consulting Fee | $80,266.91 |
| Food and Beverage | $23,287.27 |
| Education | $312.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $668,633.53 | 2019-2025 | Evenity, Prolia, Krystexxa |
| Abbvie INC. | $381,863.15 | 2019-2025 | Skyrizi, Rinvoq |
| Ucb, INC. | $157,624.75 | 2019-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $114,967.18 | 2019-2025 | |
| Glaxosmithkline, LLC. | $107,642.07 | 2019-2025 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33,061.48 | 2020-2025 | Ofev, Cyltezo |
| Genzyme Corporation | $22,304.94 | 2019-2024 | |
| Kyowa Kirin, INC. | $12,999.65 | 2024-2025 | Crysvita |
| Regeneron Healthcare Solutions, INC. | $1,113.00 | 2019 | |
| Janssen Biotech, INC. | $989.97 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $679.68 | 2019-2025 | Taltz, Omvoh |
| Alexion Pharmaceuticals, INC. | $565.98 | 2024-2025 | Strensiq |
| Pacira Therapeutics, INC. | $334.73 | 2019-2021 | |
| Radius Health, INC. | $278.16 | 2019-2025 | Tymlos |
| Astrazeneca Pharmaceuticals Lp | $258.84 | 2022-2025 | Saphnelo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $161.09 | 2019-2025 | Actemra |
| Sanofi-Aventis U.S. LLC | $146.40 | 2019-2023 | |
| Fresenius Kabi USA, LLC | $105.20 | 2023-2025 | Idacio |
| E.R. Squibb & Sons, L.L.C. | $103.43 | 2019-2024 | Orencia |
| Horizon Therapeutics Plc | $100.45 | 2019-2023 | Krystexxa |
| Sandoz INC. | $89.83 | 2023-2025 | Hyrimoz, Jubbonti |
| Pfizer INC. | $72.64 | 2019 | |
| Kerecis Limited | $57.15 | 2020 | |
| Abbott Laboratories | $39.90 | 2021 | |
| Aurinia Pharma U.S., INC. | $28.79 | 2025 | Lupkynis |
| Alvogen INC | $20.45 | 2025 | Teriparatide |
| Biocon Biologics INC | $19.05 | 2024 | Hulio |
| Mallinckrodt Hospital Products INC. | $17.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Siegel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.